Pathological complete response and prognostic predictive factors of neoadjuvant chemoimmunotherapy in early stage triple-negative breast cancer

作者：Xuwei Chen, Hengming Ye, Daming Xu, Siqi Chen, Wei Wu, Xiaoyu Qian, Xinyu Zhang, Xuxiazi Zou, Junquan Chen, Xi Wang · 发表于：Frontiers in Immunology · 年份：2025 · DOI：10.3389/fimmu.2025.1570394 · 被引用次数：7 · 研究领域：Breast Cancer Treatment Studies、Inflammatory Biomarkers in Disease Prognosis、Breast Lesions and Carcinomas

Background Neoadjuvant chemoimmunotherapy (nCIT) has shown promise in treating early-stage triple-negative breast cancer (eTNBC), but predictive biomarkers for pathological response and prognosis remain poorly defined. Objective This study aimed to explore pathological complete response and prognostic predictive factors in eTNBC patients treated with nCIT. Materials and methods We retrospectively analyzed 112 eTNBC patients who underwent surgery after nCIT at Sun Yat-sen University Cancer Center between June 2019 and June 2023. Pathological response was assessed using Miller-Payne grade. Clinicopathological features and hematologic markers were analyzed with univariate and multivariate logistic regression or Cox regression, as well as Kaplan-Meier survival curves. Objective response rate (ORR), pathological complete response (pCR), and disease-free survival (DFS) were evaluated. Nomograms predicting pCR and DFS were constructed based on significant risk factors and the systemic inflammatory response index (SIRI). Results Higher baseline lymphocyte counts ( P =0.004) were independently associated with a higher pCR rate, while elevated monocyte counts ( P =0.006), neutrophil-to-lymphocyte ratio ( P =0.005), platelet-to-lymphocyte ratio (p = 0.005), SIRI ( P =0.037), systemic immune-inflammation index ( P =0.029), and preoperative SIRI ( P =0.010) were associated with a lower pCR rate. Higher baseline SIRI ( P = 0.009) was correlated with shorter DFS, while higher preoperative l...